Work

Case report of two patients with refractory HIV-related B-cell lymphoma treated with the monoclonal antibody glofitamab for secondary central nervous system involvement

Year: 2026

Type: article

Abstract: Diffuse large B-cell lymphoma (DLBCL), the most common type of human immunodeficiency virus (HIV)-related lymphoma, is associated with a high risk of central nervous system (CNS) involvement. Studies have shown that CD20×CD3 bispecific antibodies have significant therapeutic efficacy in refractory B-cell lymphoma. Preliminary reports indicate that the monoclonal antibody glofitamab can penetrate the blood-brain barrier, inducing clinical responses in CNS DLBCL patients by activating T lymphocytes. This report presents preliminary clinical evidence on the use of glofitamab in HIV-positive patients with secondary CNS lymphoma.

Source: Frontiers in Oncology

DOI: 10.3389/fonc.2025.1699475

Authors: Yueru Ji, Jing Gao, Tong Wei, Miaowang Hao, Weiwei Qin

Institutions: Tang Du Hospital, Air Force Medical University

Language: English

Topic: CNS Lymphoma Diagnosis and Treatment

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,801